CureDuchenne & Edgewise Therapeutics: A Novel Approach to Protect Muscle in Duchenne & Becker

Join Edgewise Chief Scientific Officer and Chief Medical Officer to learn more about the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The presentation highlights the mechanism of action, results from the ongoing open label ARCH study in adults with Becker muscular dystrophy, and upcoming trials.